Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027651 (
tumor
)
685,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Two chalcone tetramers were isolated as inhibitors of Epstein-Barr virus (EBV)-activation induced by a
tumor
promoter, teleocidin B-4, from a medicinal plant in tropical west Africa, Lophira alata (Ochnaceae). One of them was identified as lophirachalcone. The other, named alatachalcone, was new, and the structure was determined by spectral properties. Both compounds also showed potent inhibitory activities against teleocidin B-4-induced inflammation on mouse ear. In an initiation-promotion experiment on mouse skin, alatachalcone (16 nmol) significantly inhibited
tumor
promotion caused by 12-O-tetradecanoylphorbol-13-acetate (
TPA
, 1.6 nmol).
...
PMID:Chalcone tetramers, lophirachalcone and alatachalcone, from Lophira alata as possible anti-tumor promoters. 136 83
TPA
(12-O-tetradecanoylphorbol-13-acetate), a potent
tumor
promoter, has been shown to stimulate or inhibit cell growth depending on the cell type investigated. We recently found that RT101 cells, a transformed mouse JB6 epidermal cell line, acquired a greater growth inhibition response to
TPA
during conventional subcultivation. The growth of low-passage RT101 cells was slightly inhibited by
TPA
in monolayer culture but stimulated in soft agar. In contrast, the growth of high-passage cells was greatly inhibited by
TPA
in both monolayer culture and in soft agar. Inhibition was dose dependent, directly correlated with protein kinase C-activating activities of
tumor
promoters, and was found to be reversible.
TPA
-treated high-passage cells were greatly reduced in volume, showed extensive abnormal mitoses, and were more susceptible to detachment. High-passage cells were also found to be less tumorigenic as indicated by in vivo tumorigenicity assay in nude mice.
TPA
treatment rendered cells still less tumorigenic in the case of both cell lines. The mechanism for acquisition of increased sensitivity to
TPA
of RT101 cells during subculture was investigated; it involved nonrandom DNA damage and detachment of nonviable cells. The results suggest the possibility that early-passage RT101 cells contained two subpopulations, one
TPA
-sensitive and one
TPA
-resistant population. Conventional subcultivation may have selected for the former subpopulation. The sensitive subpopulation may have been irreversibly inhibited as a result of
TPA
-induced cell killing, possibly apoptosis.
...
PMID:Acquisition of a growth-inhibitory response to phorbol ester involves DNA damage. 137 31
Serum levels of squamous cell carcinoma antigen, carcinoembryonic antigen, CA 125, tissue polypeptide antigen, CRP, alpha 1-antitrypsin and haptoglobin were determined peri- and postoperatively in patients undergoing surgery for benign gynecological disease (n = 18) and postoperatively in women operated for cervical carcinoma (n = 23). The only significant changes seen after premedication, during anesthesia and during surgery were a decrease in serum concentrations of alpha 1-antitrypsin and haptoglobin. We found no postoperative changes in the serum levels of squamous cell carcinoma antigen nor in carcinoembryonic antigen values. However, the latter analyte was influenced by smoking habits. Elevated levels of CA 125 and tissue polypeptide antigen were found in the cancer patients, predominantly within the first 1-3 weeks after surgery. These levels decreased to normal values within 4-6 weeks postoperatively. The median intraindividual coefficients of variation for the
tumor
markers ranged between 15% and 28% in 30 control women not having surgery. In general, it would seem advisable to wait 6 weeks after surgery before monitoring with CA 125 and
TPA
is started.
...
PMID:Peri- and postoperative changes in serum levels of four tumor markers and three acute phase reactants in benign and malignant gynecological diseases. 137 4
We investigated the efficacy of IL-2, LPS, MDP, TRA, ionomycin and contrykal on proliferation of lymphocytes treated by
tumor
cell immunosuppressive factors (ISF). IL-2, LPS and/or MDP did not abolish the influence of P815 and B16 ISF on Con A or alloantigen-induced lymphocyte proliferation.
TPA
and in less extent ionomycin and combination of the above preparations totally abrogated the suppression of Con A-induced lymphocyte proliferation. In inverted experiments Con A abrogated ISF-mediated suppression of lymphocyte proliferation induced by
TPA
plus ionomycin.
...
PMID:[Study of the possibility to abolish the action of immunosuppressive factors of tumor cells]. 138 95
In this study we measured eight different
tumor
markers (PSA, PAP,
TPA
, CEA, Ca 50, Ca 19-9, Ca 125 and Ca 15-3) in 39 patients with prostatic adenocarcinoma and in 90 patients with benign prostatic hyperplasia. We then calculated the sensitivity and specificity for each
tumor
marker separately and found that only PSA, when we consider as normal value 10 ng/ml, has a sufficiently high sensitivity and specificity. Our conclusion is that only PSA can be used for diagnostic purposes in conjunction with other diagnostic modalities.
...
PMID:Efficacy of eight serially measured markers for diagnosis of prostatic carcinoma. 138 39
Treatment of Hela cells infected with adenovirus 5 wild type (Ad5WT) with the
tumor
-promoting phorbol ester
TPA
(12-O-tetradecanoyl phorbol-13-acetate), accelerated as well as stimulated expression of viral early genes EII and EIII but not that of EIA.
TPA
treatment of HeLa cells infected with dl312, an Ad5 EIA deletion mutant, activated expression of EIII but not EII. Stimulation of EII and EIII expression was blocked by H7 (1-5-isoquinolinyl sulfonyl-2-methyl piperazine), a specific inhibitor of protein kinase c (PKc). Nuclear run off assays demonstrated that
TPA
exerted a stimulatory effect at the level of transcription. PKc inhibitor alone reduced transcription of early genes in the absence of
TPA
activation. Phosphorylation of EIA 35 kDa but not 40- to 45-kDa proteins was dramatically increased by
TPA
. Three cellular proteins of 200, 24, and 20 kDa which coprecipitated with EIA proteins underwent enhanced and preferential phosphorylation by activated PKc. Inhibitor of PKc blocked phosphorylation of cellular proteins and reduced phosphorylation of EIA 35 kDa but not EIA 40- to 45-kDa proteins. These results tend to indicate that
TPA
stimulates adenovirus early gene expression through activation of protein kinase c and further suggest but do not prove that this may be due to specific phosphorylation of EIA 35 kDa and cellular proteins of 200, 24, and 20 kDa.
...
PMID:Stimulation of adenovirus early gene expression by phorbol ester: its possible mechanism. 138 51
E26 is an acute avian leukemia virus that contains two nuclear oncogenes, v-myb and v-ets, and that is capable of transforming early cells of the erythroid and myeloid lineages. In another study, we have found that
TPA
(phorbol 12,13-dibutyrate) treatment of E26-transformants displaying an 'early erythroid' phenotype results in the production of cells with either myeloid or eosinophil characteristics. To analyze this induction in greater detail we have produced a panel of four monoclonal antibodies against E26-transformants before and after
TPA
-induced differentiation. Two antibodies, MEP21 and MEP26, reacted with proteins of 150 and 47-60 kDa, respectively, which are expressed on the surface of E26 progenitor cells but whose expression is extinguished following
TPA
-induced differentiation. A third antibody, EOS47, recognizes a 100 kDa molecule that is expressed on the surface of
TPA
-induced peroxidase positive cells (an enzyme that in avian species is restricted to cells of the eosinophilic lineage). MEP21, MEP26, and EOS47 do not react with lymphoid, myeloid, or more mature erythroid lineage cell lines. The fourth antibody, MEP17, recognizes a heterodimer of 140 and 150 kDa chains which is expressed at high levels by E26-transformed progenitor cells and at lower levels by
TPA
-induced cells. Further biochemical characterization of the MEP17 antigen revealed a structure similar to that of the leukocyte adhesion molecule VLA-4; a member of the integrin family of adhesion proteins. All four antibodies react with subpopulations of cells in the bone marrow and spleens of 1-day-old chickens. Although the MEP21 and MEP26 antibodies do not appear to react with mature cells of most hematopoietic lineages they are expressed at high levels by mature thrombocytes. In addition, MEP17 is expressed at high levels by the majority of bursal B-cells, thrombocytes, and more weakly by thymocytes. The reagents described should be useful as markers for the study of development, migration, and differentiation of normal avian hematopoietic progenitor cells and eosinophilic precursors, and for the study of retrovirus-induced
neoplasia
.
...
PMID:Cell surface proteins of chicken hematopoietic progenitors, thrombocytes and eosinophils detected by novel monoclonal antibodies. 140 65
Enzyme characteristics of in vitro activated peritoneal macrophages of normal and BP6-TU2
tumor
-bearing rats were compared with those of nonactivated macrophages. The activating effect of LPS, IFN-gamma, IL-2,
TPA
, TNF and Zymosan was assessed by the determination of the activities of alpha-naphthyl butyrate esterase (ANBE), tartrate-resistant acid phosphatase (TRAP), beta glucuronidase (BG) and 5'nucleotidase (5'NT). The used individual activators induced the macrophage enzyme activities in different degrees. LPS,
TPA
and TNF appeared to be the most effective activators of enzyme activities in macrophages of normal rats. IFN-gamma, IL-2 and Zymosan were less effective. The macrophages of BP6-TU2
tumor
-bearing rats were less sensitive to the stimulatory effect of activators with respect to their enzyme activation capacity, except for TRAP activity. The results indicate that enzyme ANBE is an adequate marker of rat peritoneal macrophages. Enzyme TRAP determines the macrophage activation degree more expressively, in comparison with BG and 5'NT. The differences in enzyme activities could be a suitable marker of macrophage activation and might suggest the dependence on the pathway of macrophage stimulation by distinct activators.
...
PMID:Cytochemical study of activated peritoneal macrophages in normal and tumor-bearing rats. 143 43
Our laboratory has been studying cancer chemopreventive effects of polyphenolic fraction isolated from green tea (GTP). In prior studies we have shown that (a) GTP possesses antigenotoxic effects in various test systems; (b) topical application of GTP protects against UV radiation and chemical carcinogen-induced tumorigenesis in murine skin; and (c) feeding of GTP in drinking water p.o. to mice protects against carcinogen-induced forestomach and lung tumorigenesis. Recently, we showed that in a dose-dependent manner GTP inhibits
tumor
promoter-caused induction of epidermal ornithine decarboxylase activity in SENCAR mice (R. Agarwal et al., Cancer Res., 52: 3582-3588, 1992). In the present study, we assessed the effect of GTP on
TPA
-induced skin tumor promotion in 7,12-dimethylbenz(a)anthracene-initiated SENCAR mouse. Topical application of varying doses of GTP (1-24 mg) 30 min prior to that of each
TPA
application resulted in highly significant protection against skin tumor promotion in a dose-dependent manner. The animals pretreated with GTP showed substantially lower
tumor
body burden such as decrease in total number of tumors per group, number of tumors per animal,
tumor
volume per mouse, and average volume per
tumor
, as compared to the animals that did not receive GTP. Since
TPA
-induced epidermal cyclooxygenase and lipoxygenase activities and edema and hyperplasia are conventionally used markers of skin tumor promotion, we also assessed the effect of preapplication of GTP on these parameters. As quantitated by the formation of prostaglandin and hydroxy-eicosatetraenoic acid metabolites from, respectively, cyclooxygenase- and lipoxygenase-catalyzed metabolism of arachidonic acid, skin application of GTP to SENCAR mice resulted in significant inhibition of
TPA
-caused effects on these 2 enzymes. Prior application of GTP to mouse skin also resulted in 30-46% inhibition of
TPA
-induced epidermal edema and hyperplasia. The results of the present study suggest that GTP possesses anti-skin tumor-promoting effects, and that the mechanism of such effects may involve inhibition of
tumor
promoter-induced epidermal ornithine decarboxylase, cyclooxygenase and lipoxygenase activities, edema, and hyperplasia. Further studies are in progress to define which component present in GTP is responsible for its anti-skin tumor-promoting effects.
...
PMID:Inhibition of 12-O-tetradecanoylphorbol-13-acetate-caused tumor promotion in 7,12-dimethylbenz[a]anthracene-initiated SENCAR mouse skin by a polyphenolic fraction isolated from green tea. 145 78
This study was performed in order to assess the relative role of cholestasis in increasing some serum glycoproteic markers of malignancy (CA 19-9,
TPA
, CEA). 30 Patients with benign and 16 with malignant extra-hepatic cholestasis were studied on admission (stage A) and after the operative or spontaneous resolution of the cholestatic picture (stage B). CA 19-9 and
TPA
were found to be lower in stage B than in stage A benign diseases. A similar behaviour was found in malignant diseases, although findings were significant only for CA 19-9. In neither of the patient groups was CEA found to present a significant trend. Extra-hepatic cholestasis appears able to increase per se serum glycoproteic markers in benign diseases, with variations proportional to the severity of the clinical picture. The same considerations can apply to malignancies, even if in these situations the production of tumour markers by the
neoplastic growth
should also be considered. We should therefore be cautious in assessing the diagnostic usefulness of new tumour markers when cholestasis is present.
...
PMID:Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases. 147 51
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>